Companies in the oncology drug
market are increasing their product innovation through strategic
collaborations. To sustain in the increasingly competitive oncology drug
market, companies are developing innovative products as well as sharing skills
and expertise with other companies. While companies have long collaborated with
each other as well as academic and research institutions in this market by
striking partnering, in or out licensing deals, this trend may have increased
in recent years. For instance, in January 2016, AstraZeneca and Moderna
Therapeutics entered into a collaboration to discover, co-develop and
co-commercialize immuno-oncology mRNA therapeutics for the treatment of
cardiovascular, metabolic and renal diseases as well as selected targets in
oncology. Servier and Novartis have also extended their collaboration to
co-develop and commercialize anti-Mcl-1 drug candidates for cancer treatment.
THE BUSINESS RESEARCH COMPANY
EXPECTS THE GLOBAL
ONCOLOGY DRUGS MARKET TO GROW TO $167 BILLION BY 2021
North America was the largest
region in the oncology drugs market in 2017, accounting for one-third of the market
share. North America has the highest GDP that allows it to afford the latest and patented
oncology medicines which are comparatively higher or difficult to access when
compared with other regions.
Order the report at: https://www.thebusinessresearchcompany.com/report/oncology-drugs-global-market-report-2018
The chart below shows the
year-on-year growth of the global oncology drugs market during 2017 – 2021
According to The Business Research
Company’s Consultant, Nitin Gianchandani, Companies are increasingly using
cancer biomarkers in the drug development process. Cancer biomarkers are
molecules secreted by a tumor or a specific response of the body to the
presence of cancer. Identifying and targeting these can enhance cancer detection
and facilitate high-speed noninvasive diagnosis using genomics and proteomics
tools. It can also help predict the drug efficacy faster than conventional
clinical endpoints, the point at which an undesired or abnormal effect of the
drug is observed indicating withdrawal from therapy. Companies in this market
are investing in the development of biomarkers for use in various activities
such as tracking drug activity, the pharmacodynamics of drugs and to study
diseases and treatment pathways. For instance, Nektar Therapeutics is
developing and using biomarkers in drug development processes of its pipeline
drugs NKTR-214 and NKTR-181. Janssen’s research & development is also
focusing on identifying predictive markers or stratification markers to help
target the new therapies.
Download a sample of the report
at:
F. Hoffmann-La Roche was the largest competitor in the oncology drugs
market in 2017, with revenues of $21.8 billion for the financial year
2016. Roche’s growth strategy
aims at increasing revenues from its laboratory business by introducing new
medicines into the market. In 2016, the company launched four new medicines
Cotellic, Alecensa, Venclexta and Tecentriq. In addition, five FDA breakthrough
designations were granted for Roche medicines in 2016.
Oncology deals with diagnosis,
prevention and treatment of cancer diseases. Anti-cancer or anti-neoplastic
agents are the drugs that prevent or inhibit or halt the proliferation and
maturation of neoplasms, an abnormal growth of tissues commonly referred as
tumors. These drugs prevent the growth of malignant tumors by affecting the
process of cell division or by damaging the DNA and initiate apoptosis or by
preventing the development and spread of neoplastic cells. Several types of cancers
that can be treated by oncology drugs are blood cancer, lung cancer, endocrine
cancer, bone cancer, gastric cancer, colorectal cancer, skin cancer, breast
cancer, pancreatic cancer, prostate cancers, ovarian cancer, ocular cancer and
others
Oncology
Drugs Global Market Report 2018 is a detailed report giving a unique insight
into this market. The report is priced at $4000 for an individual user. To use
across your office, the price is $6000 and $8000 if you wish to use across a
multinational company.
About The Business Research Company:
Visit TheBusinessResearchCompany.com,
mail info@tbrc.info or call +447443439350 or
+918897263534 or +919160996838 for more information on this and many other
titles.
The Business Research Company is a
market research and intelligence company, which excels in company, market and
consumer research.
It has research professionals at its
offices in the UK, India and the US as well a network of trained researchers
globally. It has specialist consultants in a wide range of industries including
manufacturing, healthcare, chemicals and technology.
The Business Research Company's
management has more than 20 years of varied business research experience. They
have delivered hundreds of research projects to the senior management of some
of the world's largest organizations.
Contact Information:
The
Business Research Company
Europe:
+44 207 1930 708
Asia:
+91 8897263534
Americas:
+1 315 623 0293
Email: info@tbrc.info
No comments:
Post a Comment